The Supreme Court, on Thursday, asked the Centre to form a panel to form statutory regulations against unethical practices by pharmaceutical companies. This includes gift giving, hospitality, and other incentives offered to doctors. A bench of Justices Vikram Nath and Sandeep Mehta issued the direction while hearing a petition seeking stronger regulation of pharmaceutical marketing practices. The court wants the committee to recommend whether, and how, the unethical interactions between pharmaceutical companies and doctors should be brought under a legally enforceable framework. The matter will resume in court on January 29, 2027, when the Centre is expected to show compliance with the directions. What Did The Supreme Court Say? Also read: Could This Popular Joint Supplement Turn Mild Cognitive Impairment Into Dementia? New Study Finds LinkThe court's order follows earlier concerns about whether the existing system is equipped to prevent unethical pharmaceutical marketing. Justice Sandeep Mehta, reading out the order, said, “We have directed the Union of India to constitute the committee and give its recommendations in terms of our previous directives and observations.” The committee will examine the representations received and make recommendations to the Union government on the need for statutory regulation. The Court had reserved order after Solicitor General Tushar Mehta informed the Court that the Union government is to form a three-member committee to assess whether a statutory framework is needed to regulate unethical practices by pharmaceutical companies. The case was filed by the Federation of Medical and Sales Representatives' Associations of India (FMRAI), which has sought accountability for alleged practices such as expensive gifts, foreign trips, hospitality and other benefits used to promote medicines to doctors. It said, “This has led to over-prescription of drugs resulting in a serious infringement of the right to life and the right to health of the citizens.” What Are Pharma Freebies To Doctors? Also read: Russia Denies Second Plague Case As WHO Seeks Answers On Lab Death; Trump Says It’s Not A BioweaponPharmaceutical companies use various marketing strategies to promote their products to healthcare professionals. These can include gifts, hospitality, sponsored travel, benefits related to conference and other promotional incentives. The concern before the Supreme Court is not just an ordinary interaction between drug companies and doctors, but whether financial or material incentives can unethically influence drug-prescribing decisions. India already has the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024, which lays down rules concerning gifts, physician samples, brand reminders, continuing medical education and other promotional activities. However, questions remain over whether the framework has adequate statutory regulation. The Centre has previously said the UCPMP is functioning, but agreed that the question of giving pharmaceutical marketing regulation statutory backing should be examined separately. The Centre, in its response, said, “The Department of Pharmaceuticals has issued the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), which is applicable to Pharmaceutical Companies, medical representatives and agents.” The code clearly prohibits pharmaceutical companies from offering gifts, travel facilities, hospitality, cash or monetary grants to physicians or their family members, it added. Unethical Pharma Marketing Could Affect PatientsThe biggest concern is that a prescribing decision could become influenced by factors other than clinical need, evidence, safety, and cost. If incentives influence prescribing, patients could potentially face: Unnecessary medicines when they are not clinically neededMore expensive branded drugs when alternatives existHigher doses or longer treatment than necessaryPolypharmacy, or the use of multiple medicines when fewer may be appropriateHigher out-of-pocket healthcare expensesThese concerns have previously been raised before the Supreme Court in relation to alleged pharmaceutical marketing practices. The issue, therefore, goes beyond ethics for patients. The doctor-pharma relationship can directly affect what medicine a patient receives, how long they take it, and how much they pay.